Mersana Therapeutics's Return On Capital Employed Insights
Portfolio Pulse from Benzinga Insights
Mersana Therapeutics reported Q1 sales of $7.80 million and a loss of $56.16 million, a 25.02% decrease from last quarter. The company posted a negative ROCE of -0.87%, suggesting inefficient capital allocation. Q1 earnings per share were $-0.52, missing analyst predictions of $-0.44.
May 24, 2023 | 2:50 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Mersana Therapeutics reported a 25.02% decrease in earnings and a negative ROCE of -0.87%, suggesting inefficient capital allocation. Q1 EPS missed analyst predictions.
Mersana Therapeutics' negative ROCE of -0.87% indicates inefficient capital allocation, which can negatively impact the company's long-term performance. Additionally, the company missed analyst predictions for Q1 EPS, which may cause short-term downward pressure on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100